The European Medicines Agency Committee for Medicinal Products for Human Use (CHMP) has taken a positive approach towards recommending a conditional marketing authorization for the use of brentuximab vedotin for treating adult patients afflicted with relapsed or refractory Hodgkin lymphoma. According to the researchers, "the antitumor activity of brentuximab vedotin has been established in Hodgkin lymphoma...the different clinical endpoints demonstrated clinical benefit in terms of disease control, resolution of B-symptoms and in terms of enabling further potentially curative treatment options." Despite common side effects, including fatigue, nausea, diarrhea, and vomiting, there is a favorable benefit-to-risk balance for considering this drug as an anti-cancer agent.
To read more about this study, click here.
No comments:
Post a Comment